Epidermal growth factor receptor-targeted agents have also shown promise in the treatment of patients with bronchioalveolar carcinoma (BAC), which is considered to be a subtype of adenocarcinoma of the lung without pleural, stromal or vascular invasion (World Health Organization classification). Here, EGFR is linked to minimally invasive lung adenocarcinoma.